# Dose EScalation Induction of EvERolimus

> **NCT02387099** · PHASE2 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 156 (actual)

## Conditions studied

- Breast Cancer
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** 3 weeks Dose Induction of Everolimus
- **DRUG:** 3 weeks Conventional Everolimus Dosing
- **DRUG:** Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
- **DRUG:** Standard Care after 24 weeks

## Key facts

- **NCT ID:** NCT02387099
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2021-05
- **Final completion:** 2021-07
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2022-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02387099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02387099, "Dose EScalation Induction of EvERolimus". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT02387099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*